English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Incomplete systemic lupus ( iSLE ) is an acknowledged condition of patients with clinical signs of lupus who do not fulfill classification criteria for  SLE . Some patients with  iSLE  have persistent mild disease, but others have serious organ involvement, and up to 55% progress to established  SLE . Research on this subject could reveal predictive or diagnostic biomarkers for  SLE . Ideally, it would become possible to discern those patients with critical organ involvement or a high risk for progression to  SLE . This high‐risk group might benefit from early treatment, which would preferably be confirmed in randomized controlled trials. This process would, however, require agreement on a definition of  iSLE . The Systemic Lupus International Collaborating Clinics ( SLICC ) classification criteria was composed in order to diagnose  SLE  earlier. The present review outlines the clinical characteristics of  iSLE  after introduction of  SLICC  criteria and furthermore proposes a definition of  iSLE  with the aim of discriminating the high‐risk group from those with a lower risk.

arthritis care and research

Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?